Research graph
References from JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study. Local targets link to admitted publications; unresolved targets remain external evidence.
Chronic active Epstein-Barr virus disease
10.3389/fimmu.2017.01867 · 2017 · External reference
The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms
10.1038/s41375-022-01620-2 · 2022 · External reference
Interferon-γ produced by EBV-positive neoplastic NK-cells induces differentiation into macrophages and procoagulant activity of monocytes, which leads to HLH
10.3390/cancers13205097 · 2021 · External reference
EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases
10.1182/blood-2011-10-381921 · 2012 · External reference
Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD
10.1111/j.1440-1827.2008.02213.x · 2008 · External reference
Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification
10.1182/bloodadvances.2020001451 · 2020 · External reference
Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan
10.1002/ajh.26544 · 2022 · External reference
Hematopoietic stem cell transplantation for adults with EBV-positive T- or NK-cell lymphoproliferative disorders: efficacy and predictive markers
10.1038/bmt.2016.3 · 2016 · External reference
What does Stat3 do?
10.1172/jci0215650 · 2002 · External reference
STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target
10.18632/oncotarget.25780 · 2018 · External reference
EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood
2017 · External reference
Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay
10.1128/jcm.37.1.132-136.1999 · 1999 · External reference
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children's Oncology Group phase 1 consortium study (ADVL1011)
10.1002/pbc.25575 · 2015 · External reference
The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation
10.1016/0092-8674(86)90803-2 · 1986 · External reference
Novel mouse xenograft models reveal a critical role of CD4 T cells in the proliferation of EBV-infected T and NK cells
10.1371/journal.ppat.1002326 · 2011 · External reference
Practical Bayesian guidelines for phase IIB clinical trials
10.2307/2533377 · 1994 · External reference
A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers
10.1007/s12185-013-1280-5 · 2013 · External reference
Ruxolitinib in patients with chronic active Epstein-Barr virus infection: a retrospective, single-center study
10.3389/fphar.2021.710400 · 2021 · External reference
How we treat chronic active Epstein-Barr virus infection
10.1007/s12185-017-2192-6 · 2017 · External reference
The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers
10.1177/0091270010389469 · 2011 · External reference
EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis
10.5045/br.2019.54.4.282 · 2019 · External reference
First case of classical Hodgkin-like EBV-positive lymphoproliferative disorder under ruxolitinib therapy
10.1002/ajh.26026 · 2021 · External reference
Elevated circulating levels of the interferon-γ-induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset Still's disease
2017 · External reference
Emapalumab in children with primary hemophagocytic lymphohistiocytosis
10.1056/nejmoa1911326 · 2020 · External reference
IP-10/CXCL10 and MIG/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome
10.1007/s00277-013-1878-y · 2014 · External reference
